Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
REDWOOD CITY, Calif., Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the U.S. Food and Drug Administration (FDA) cleared its sacroiliac joint fusion device, which will be marketed as Nevro1, without the need to include the screw ("NevroFix™").
- Nevro1, an integrated transfixing technology, is proven to immediately transfix the SI joint to allow the opportunity for long-term fusion.
- Self-contained, deployable titanium anchors transfix the sacrum and ilium to enhance axial and rotational stability of the joint.
- In addition, Nevro's proprietary instrumentation allows for optimal intra-articular SI joint preparation which is critical to achieve joint fusion.
- The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.